Many stakeholders believe innovation only leads to generating new molecules, but innovation can also come from other areas such as focusing on improving present molecules which are no longer protected by patent.
There is significant untapped potential in Europe to optimise existing therapies and value added medicines represent an opportunity for patients, healthcare providers, payers, industry and the healthcare systems in general.
